SUTRO BIOPHARMA, INC.
STROSutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How STRO's past catalysts played out
No drugs found in this phase.
Frequently asked questions
When is SUTRO BIOPHARMA, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for SUTRO BIOPHARMA, INC. (STRO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track STRO biotech catalysts?→
Add STRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SUTRO BIOPHARMA, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.